Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for mitomycin C (compound)


PubChem
Name: Mitomycin
PubChem Compound ID: 231224
Description: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
Molecular formula: C15H18N4O5
Molecular weight: 334.327 g/mol
Synonyms:
50-07-7; Mit-C; NSC26980; Ametycin; MMC; Mitomycin; Ametycine; Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4, 7-dione, 6-amino-1,1a,2,8,8a,8b-hexahydro-8- (hydroxymethyl)-8a- methoxy-5-methyl-, carbamate (ester) (VAN 8CI); NCI-C04706; Mitomycinum.
show more »
DrugBank
Identification
Name: Mitomycin
Name (isomeric): DB00305
Drug Type: small molecule
Description: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
Synonyms:
Mitamycin; MMC; 7-Amino-9α-methoxymitosane
Brand: Ametycin, Mitosol, Muamycin, Mitomycinum, Mitomycyna C [Polish], Mitocin-C, Mitomycin C, Mutamycin, Mytomycin, Mit-C, Mytozytrex, Mito-C, Ametycine, Mitomycinum C, Mitomycin (TN), Mitomycin-C, Mitozytrex
Category: Cross-Linking Reagents, Antibiotics, Antineoplastic, Alkylating Agents, Nucleic Acid Synthesis Inhibitors
CAS number: 50-07-7
Pharmacology
Indication: For treatment of malignant neoplasm of lip, oral cavity, pharynx, digestive organs, peritoneum, female breast, and urinary bladder. Also used as an adjunct to ab externo glaucoma surgery.
Pharmacology:
Mitomycin is one of the older chemotherapy drugs, which has been around and in use for decades. It is an antibiotic which has been shown to have antitumor activity. Mitomycin selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of mitomycin-induced cross-linking. At high conc...
show more »
Mechanism of Action: Mitomycin is activated in vivo to a bifunctional and trifunctional alkylating agent. Binding to DNA leads to cross-linking and inhibition of DNA synthesis and function. Mitomycin is cell cycle phase-nonspecific.
Absorption: Erratic.
Biotransformation: Primarily hepatic, some in various other tissues.
Route of elimination: Approximately 10% of a dose of mitomycin is excreted unchanged in the urine.
Half Life: 8-48 min
Toxicity: Oral, mouse: LD50 = 23 mg/kg; Oral, rat: LD50 = 30 mg/kg. Symptoms of overdose include nausea and vomiting.
Affected organisms: Humans and other mammals
Interactions
Drug interaction:
VindesinePotentially severe lung toxicity
VincristinePotentially severe lung toxicity
TrastuzumabTrastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
VinblastinePotentially severe lung toxicity

Targets


Enzymes


Transporters